ArticleBiomaterials2020
Targeted melanoma radiotherapy using ultrasmall
Open access · greenAbstract read
In one paragraph
Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use.Biomolecules · 2023Pooled it
- Nanoparticle-Based Treatment Approaches for Skin Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2023Pooled it
- Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026Review
- An ultrasmall core-shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments.Nature nanotechnology · 2026Article
- Melanoma treatment in the era of nanotechnology and precision medicine.Journal of nanobiotechnology · 2025Review
- Designing the Next Generation of Biomaterials through Nanoengineering.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- Protein-functionalized and intrinsically radiolabeled [European journal of nuclear medicine and molecular imaging · 2025Article
- Melanocortin-1 receptor expression as a predictive factor for postoperative outcomes in melanoma patients: a retrospective study.Frontiers in immunology · 2025Article
- In Vitro Assessment ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.EJNMMI radiopharmacy and chemistry · 2024Review
- Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [European journal of nuclear medicine and molecular imaging · 2024Article
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Realizing active targeting in cancer nanomedicine with ultrasmall nanoparticles.Beilstein journal of nanotechnology · 2024Review
- Approaches to Nanoparticle Labeling: A Review of Fluorescent, Radiological, and Metallic Techniques.Environment & health (Washington, D.C.) · 2023Review
- Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging.Drug delivery and translational research · 2023Review
- CeONanomaterials (Basel, Switzerland) · 2022Article
- Nanoparticles and Radioisotopes: A Long Story in a Nutshell.Pharmaceutics · 2022Review
- Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Xiuli ZhangHarry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States.
Feng ChenDepartment of Radiology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States.
Melik Z TurkerDepartment of Materials Science and Engineering, Cornell University, Ithaca, NY 14853, United States.
Kai MaElucida Oncology, New York, NY 10016, United States.
Pat ZanzonicoDepartment of Medical Physics, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States.
Fabio GallazziDepartment of Chemistry and Research Core Facilities, University of Missouri, Columbia, MO 65211, United States.
Manankumar A ShahHarry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States.
Austin R PraterHarry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States.
Ulrich WiesnerDepartment of Materials Science and Engineering, Cornell University, Ithaca, NY 14853, United States.
Michelle S BradburyDepartment of Radiology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States; Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States.
Michael R McDevittDepartment of Radiology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States.
Thomas P QuinnHarry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States. Electronic address: Quinnt@missouri.edu.
Kettering University · USHarry S. Truman Memorial Veterans' Hospital · USCornell University · USUniversity of Missouri · USNew York Oncology Hematology · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MReal-time Intraoperative Imaging of Cancer Biomarkers and Peripheral NervesU54CA199081 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WIESNER, ULRICH · 2015 to 2019
$8.3MRenally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective RaR01CA161280 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BRADBURY, MICHELLE S, WIESNER, ULRICH · 2012 to 2016
$2.7MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA161280NCI NIH HHS U54 CA199081
Abstract
Lutetium-177 (
Indexed as
MelanomaMelanoma, ExperimentalNanoparticlesalpha-MSHAnimalsCell Line, TumorHumansSilicon DioxideTissue Distributionalpha-MSHSilicon DioxideMelanomaRadionuclide therapyUltrasmall silica nanoparticleα-melanocyte stimulating hormone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.